跳转至内容
Merck
CN

H1120000

肼屈嗪 盐酸盐

European Pharmacopoeia (EP) Reference Standard

别名:

1-肼基二氮杂萘 盐酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C8H8N4 · HCl
化学文摘社编号:
分子量:
196.64
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

pharmaceutical primary standard

API family

hydralazine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl[H].N\N=C1/N=NC=C2C=CC=CC12

InChI

1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5,7H,9H2;1H/b11-8-;

InChI key

SECXUXOCDLQOBI-MKFZHGHUSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Hydralazine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

抑制DNA甲基转移酶并调节基因表达的表观遗传调控。非选择性MAO-A/B抑制剂;降压药;氨基脲敏感性胺氧化酶抑制剂。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under 肼屈嗪 盐酸盐


pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Sofie Gevaert et al.
Acta cardiologica, 69(2), 193-196 (2014-05-03)
Heart failure is an established predictor of primary cardiac events during pregnancy. Adequate heart failure treatment in pregnant women is hampered by important foetotoxicity of several conventional drugs. Hydralazine with or without long-acting nitrates has been proposed as an alternative
Genetic mechanisms possibly leading to racially different responses to nitrate therapy.
Gustavo H Oliveira-Paula
The American journal of cardiology, 114(7), 1126-1126 (2014-09-13)
Keith C Ferdinand
Expert review of cardiovascular therapy, 3(6), 993-1001 (2005-11-19)
In the USA alone, there are over 5,000,000 people diagnosed with heart failure. A disproportionate number of African-Americans are affected by this disease, with increased morbidity and mortality, yet they are tremendously under-represented in clinical trials. Several drugs have been



全球贸易项目编号

货号GTIN
H112000004061833663905